Menu
 

NEURO-APP CONFERENCE

ADVANCED CARE FOR NEUROSCIENCE PATIENTS

January 5-8, 2022 | San Diego, CA OR Online

Industry Posters (Non-CE)

Once-Daily Valbenazine Is Effective for Tardive Dyskinesia in Elderly Patients (≥65 Years)

Older patients taking a dopamine-receptor blocking agent have increased risk for tardive dyskinesia (TD), a persistent and potentially disabling movement disorder. These analyses, being the first to assess the effects of an approved TD medication in elderly patients (≥65 years), indicate that long-term once-daily valbenazine is appropriate for this population.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Development of the MIND-TD Questionnaire as a Screening Tool for Tardive Dyskinesia

The MIND-TD questionnaire was developed to facilitate clinician-patient dialogues about the risks, symptoms, and impact of tardive dyskinesia (TD). Part 1 is a screening tool with questions about Movement, Impact, Notice, and Daily Activities. Part 2 includes a Thorough Interview and a Differentiation checklist to elicit more information about abnormal movements.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Evaluating Patients’ Preferences for Parkinson’s Disease Treatments

Pretest interviews were conducted to inform a broader survey on patient preferences for key attributes of adjunctive Parkinson’s disease medications. Most patients (10/15) reported they would add an adjunctive medication offering ~1.5 to 2 hours of additional “ON” time regardless of potential side effects and complication of preexisting medication regimens.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Efficacy and Safety of Once-Daily Opicapone in Older Patients with Parkinson’s Disease and Motor Fluctuations

Pooled data from 2 pivotal Phase 3 studies of opicapone in patients with Parkinson’s disease (NCT01568073, NCT01227655) were analyzed to evaluate efficacy and safety of opicapone in older participants (≥65 years). Older participants had significantly greater improvements in “OFF”-time and “ON”-time with once-daily opicapone versus placebo; opicapone was generally well-tolerated.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Evaluation of Diazepam Nasal Spray in Patients With Seizure Clusters Concomitantly Receiving Clobazam: A Subgroup Analysis From a Completed Phase 3, Long-Term, Open-Label Safety Study

The objective is to­ evaluate ­the ­long-term­ effectiveness­ and­ safety ­of­diazepam­ nasal­ spray­ as­ rescue ­medication ­for ­treatment ­of­seizure ­clusters in subgroups of patients receiving clobazam, which is used chronically, or other benzodiazepines, which are typically used intermittently in epilepsy, as part of their ASM regimen in a long-term safety study.

View the poster

Sponsored by

neurelis logo

For additional information, please contact Neurelis Medical Information at medinfo@neurelis.com.